Advances in the Management of Sepsis and the Understanding of Key Immunologic Defects

被引:100
作者
Skrupky, Lee P. [1 ]
Kerby, Paul W. [1 ]
Hotchkiss, Richard S. [1 ]
机构
[1] Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA
基金
美国国家卫生研究院;
关键词
GOAL-DIRECTED THERAPY; NECROSIS-FACTOR-ALPHA; VENTILATOR-ASSOCIATED PNEUMONIA; COMBINATION ANTIBIOTIC-THERAPY; CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; SEPTIC SHOCK; PSEUDOMONAS-AERUGINOSA; PIPERACILLIN-TAZOBACTAM; MONOCLONAL-ANTIBODY;
D O I
10.1097/ALN.0b013e31823422e8
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Anesthesiologists are increasingly confronting the difficult problem of caring for patients with sepsis in the operating room and in the intensive care unit. Sepsis occurs in more than 750,000 patients in the United States annually and is responsible for more than 210,000 deaths. Approximately 40% of all intensive care unit patients have sepsis on admission to the intensive care unit or experience sepsis during their stay in the intensive care unit. There have been significant advances in the understanding of the pathophysiology of the disorder and its treatment. Although deaths attributable to sepsis remain stubbornly high, new treatment algorithms have led to a reduction in overall mortality. Thus, it is important for anesthesiologists and critical care practitioners to be aware of these new therapeutic regimens. The goal of this review is to include practical points on important advances in the treatment of sepsis and provide a vision of future immunotherapeutic approaches.
引用
收藏
页码:1349 / 1362
页数:14
相关论文
共 112 条
  • [1] Empiric antibiotic therapy for suspected ventilator-associated pneumonia: A systematic review and meta-analysis of randomized trials
    Aarts, Mary-Anne W.
    Hancock, Jennifer N.
    Heyland, Daren
    McLeod, Robin S.
    Marshall, John C.
    [J]. CRITICAL CARE MEDICINE, 2008, 36 (01) : 108 - 117
  • [2] EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL
    ABRAHAM, E
    WUNDERINK, R
    SILVERMAN, H
    PERL, TM
    NASRAWAY, S
    LEVY, H
    BONE, R
    WENZEL, RP
    BALK, R
    ALLRED, R
    PENNINGTON, JE
    WHERRY, JC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12): : 934 - 941
  • [3] Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death
    Abraham, E
    Laterre, P
    Garg, R
    Levy, H
    Talwar, D
    Trzaskoma, BL
    Francois, B
    Guy, JS
    Bruckmann, M
    Rea-Neto, A
    Rossaint, R
    Perrotin, D
    Sablotzki, A
    Arkins, N
    Utterback, BG
    Macias, WL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (13) : 1332 - 1341
  • [4] Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock
    Annane, D
    Sébille, V
    Charpentier, C
    Bollaert, PE
    François, B
    Korach, JM
    Capellier, G
    Cohen, Y
    Azoulay, E
    Troché, G
    Chaumet-Riffaut, P
    Bellissant, E
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (07): : 862 - 871
  • [5] Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock:: a randomised trial
    Annane, Djillali
    Vignon, Philippe
    Renault, Alain
    Bollaert, Pierre-Edouard
    Charpentier, Claire
    Martin, Claude
    Troche, Gilles
    Ricard, Jean-Damien
    Nitenberg, Gerard
    Papazian, Laurent
    Azoulay, Elie
    Bellissant, Eric
    [J]. LANCET, 2007, 370 (9588) : 676 - 684
  • [6] Bundled care for septic shock: An analysis of clinical trials
    Barochia, Amisha V.
    Cui, Xizhong
    Vitberg, David
    Suffredini, Anthony F.
    O'Grady, Naomi P.
    Banks, Steven M.
    Minneci, Peter
    Kern, Steven J.
    Danner, Robert L.
    Natanson, Charles
    Eichacker, Peter Q.
    [J]. CRITICAL CARE MEDICINE, 2010, 38 (02) : 668 - 678
  • [7] Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia
    Beardsley, James R.
    Williamson, John C.
    Johnson, James W.
    Ohl, Christopher A.
    Karchmer, Tobi B.
    Bowton, David L.
    [J]. CHEST, 2006, 130 (03) : 787 - 793
  • [8] Efficacy and safety of recombinant human activated protein C for severe sepsis.
    Bernard, GR
    Vincent, JL
    Laterre, P
    LaRosa, SP
    Dhainaut, JF
    Lopez-Rodriguez, A
    Steingrub, JS
    Garber, GE
    Helterbrand, JD
    Ely, EW
    Fisher, CJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) : 699 - 709
  • [9] Pseudomonas aeruginosa infections in the Intensive Care Unit:: can the adequacy of empirical β-lactam antibiotic therapy be improved?
    Bhat, Sunil
    Fujitani, Shigeki
    Potoski, Brian A.
    Capitano, Blair
    Linden, Peter K.
    Shutt, Kathleen
    Paterson, David L.
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 30 (05) : 458 - 462
  • [10] Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms
    Bhat, Sunil V.
    Peleg, Anton Y.
    Lodise, Thomas P., Jr.
    Shutt, Kathleen A.
    Capitano, Blair
    Potoski, Brian A.
    Paterson, David L.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (12) : 4390 - 4395